|Executive Directors||Non-executive Directors||Independent Non-Executive Directors|
Mr. CHAN Ting
Mr. LIAO Zhe
Mr. CHEUK Ka Chun Kevin
Madam CHEUNG Kwai Lan
Dr. CHENG Yanjie
Mr. LAU Fai Lawrence
Dr. LIU Ta-pei
Mr. CHAU Wai Wah Fred
Madam CHEUNG Kwai Lan, aged 83, one of the founders of the Group, is the honorary chairperson and non-executive director of the Company. She has served the Group for more than 21 years and is the director of various subsidiaries of the Group. Madam CHEUNG is responsible for corporate development and strategic planning of the Group. Madam CHEUNG graduated from Shanxi Taiyuan Medical School in 1960 and was a researcher at Shanxi Province Taiyuan (Atomic Energy) Research Institute (山西省太原（原子能）研究所), which was one of the institutions of the Chinese Academy of Science. She also participated in the research and development of the radioactive material Cobalt 60 for imaging and cancer treatment. Madam CHEUNG has been engaged in commercial development in Hong Kong for almost 40 years.
Madam CHEUNG has keen interest in social welfare and charity works. She is currently the chairperson of Zhang Xueliang Foundation, permanent honorary chairperson of the World of Chinese & Overseas Chinese Peace Promote Association, director of the China Legal Aid Foundation under the Ministry of Justice, vice chairperson of the “Chinese Charitable Work Development Association” (中國公益事業發展聯合會), and honorary director of “Chinese Si Hai Tong Xin Association in Taiwan” (台灣中華四海同心會). Madam CHEUNG attended the 2nd conference of the 11th National Committee of the Chinese People’s Political Consultative Conference as an overseas compatriot by special invitation. She has also been awarded as “China Philanthropy Outstanding Contribution Individual”, “Most Influential Entrepreneur in China”, “International Philanthropic Celebrity”, “International Philanthropic Stars” and “Progeny of the PRC for the 60 Years Development of New China”.
Madam CHEUNG is the mother of Ms. CHAN Siu Sarah and Mr. CHAN Ting. Ms. CHAN Siu Sarah and Mr. CHAN Ting are the Group General Counsel and an executive director of the Company respectively.
Mr. CHAN Ting, aged 51, is the chairperson, executive director, chief executive officer, compliance officer and authorised representative of the Company. He is also the chairperson of the nomination committee of the Company and a member of the remuneration committee of the Company. He has served the Group for more than 20 years and is the director of various subsidiaries of the Group. He is responsible for the marketing, business development, strategic planning and operations of the Group. He was awarded a bachelor’s degree in Economics from Macquarie University in Australia in 1993. He is the Vice President of the Zhang Xueliang Foundation. Mr. CHAN has over 26 years of working experience in establishing and managing companies in the PRC.
Mr. CHAN is the son of Madam CHEUNG Kwai Lan, who is the honorary chairperson and non-executive director of the Company. Mr. CHAN is the brother of Ms. CHAN Siu Sarah, the Group General Counsel. He joined the Group in July 2001.
Mr. LIAO Zhe, aged 34, is an executive director and chief operating officer of the Company. He has more than 10 years of experience in the Internet industry and 1 year of experience as an executive director of a Hong Kong listed company. From 2014 to 2017, he worked in Tencent Technology (Shenzhen) Company Limited, a wholly-owned subsidiary of Tencent Holdings Limited (stock code: 700.HK), as the general manager of the financial institution in the WeChat Pay joint product department. From October 2017 to October 2018, he served as an executive director of Shunten International (Holdings) Limited (stock code: 932.HK). Mr. Liao holds a bachelor’s degree from Beijing Normal University in Zhuhai and an advanced degree from DFI Hamburg School of Design, Germany. He was appointed as the guest speaker of the Graduate School of Industrial Engineering of the University of Hong Kong in 2015, and was the founding director of the Hong Kong Young Executives Association in 2018. Mr. Liao joined the Company in September 2019. He is also the general manager of Sinopharm Health (Hainan) Technology Co., Ltd., a subsidiary of the Company. From the date of appointment, he will be fully responsible for the Company’s anti-counterfeiting business, e-commerce business, Internet technology business and related businesses.
Mr. CHEUK Ka Chun Kevin, aged 37, an executive director of the Company. He holds a bachelor’s degree in economics and a master’s degree in applied finance from Macquarie University in Australia. Mr. CHEUK has served the Group for more than 12 years and is currently as a project director of the Company. He has been responsible for the investment and acquisition of various projects of the Group. He has more than 10 years of experience in the lottery industry and technological innovation and application. He has led the team to win various awards under “Interactive In-Store Marketing Solutions” and “Health Management Cloud Platform” projects in 2016 and 2017 Geneva International Invention Exhibition respectively, including a gold award in 2016 Geneva International Invention Exhibition. He also served as a director of a subsidiary of the Company. From the date of appointment, Mr. CHEUK’s management scope will be expanded to the supply chain management and related businesses of the lottery part of the anti-counterfeiting business.
Dr. CHENG Yanjie, aged 57, is a non-executive Director of the Company. Being a practicing Chinese medicine practitioner, he holds Bachelor degree of Traditional Chinese Medicine of Changchun University of Chinese Medicine (長春中醫學院中醫系學士學位), Master of Neurology of the Affiliated Hospital of Changchun University of Chinese Medicine (長春中醫學院附屬醫院神經內科碩士學位) and Doctor of Neurology of Beijing University of Chinese Medicine Dongzhimen Hospital (北京中醫藥大學東直門醫院神經內科博士學位). He previously served as Resident Neurologist of the Affiliated Hospital of Changchun University of Chinese Medicine (長春中醫學院附屬醫院神經內科住院醫師), Attending Physician of China Medical Center in Kuwait (科威特國中國醫療中心主治醫師), Neurology attending physician of Beijing University of Chinese Medicine Dongzhimen Hospital (北京中醫藥大學東直門醫院神經內科主治醫師) and worked in the R&D department of China National Pharmaceutical Group Co., Ltd. (中國藥材集團公司). He serves as committee member of China Pharmaceutical Culture Society (中國藥文化協會理事), executive director of Beijing Chaoyang District Chinese Medicine Association (北京市朝陽區中醫協會常務理事) and expert speaker of knowledge base popularization and bilingual health lecture of Beijing Chaoyang District (北京市朝陽區中醫科普及雙語養生講座專家). Dr. CHENG is currently the Chief Physician of Chinese medicine clinic of Beijing Luxiancaotang (北京鹿銜草堂中醫診所主任醫師). He currently serves as director and consultant of Sinopharm Traditional Chinese Medicine Co. Ltd (國藥藥材股份有限公司) and a director of Bencao Lihua Investment Management Co., Ltd. (本草利華投資管理有限公司). As at the date of this annual report, Sinopharm Traditional Chinese Medicine Co. Ltd wholly owned the equity interest in Sinopharm Traditional Chinese Medicine Overseas Holdings Limited which was a substantial shareholder of the Company. He held 5% of the equity interest in Bencao Lihua Investment Management Co., Ltd. (本草利華投資管理有限公司) which is one of the shareholders of Sinopharm Traditional Chinese Medicine Co. Ltd.
Mr. LAU Fai Lawrence, aged 50, is an independent non-executive Director of the Company and a chairperson of the audit committee and remuneration committee of the Company. Mr. LAU is currently a practising certified public accountant in Hong Kong and a fellow member of the Association of Chartered Certified Accountants in the United Kingdom. Mr. LAU graduated from The University of Hong Kong with a bachelor’s degree in business administration in 1994 and obtained a master’s degree in corporate finance from Hong Kong Polytechnic University in 2007. Mr. LAU is currently the company secretary of BBMG Corporation (stock code: 2009.HK) since August 2008, an executive director of Future World Financial Holdings Limited (stock code: 572.HK) since January 2014, an independent non-executive director of Artini Holdings Limited (stock code: 789.HK) since April 2008, Titan Petrochemicals Group Limited (stock code: 1192.HK) since March 2014, Renco Holdings Group Limited (stock code: 2323.HK) since March 2016 and China Energine International (Holdings) Limited since March 2020 (stock code: 1185.HK). Mr. LAU was a non-executive director of Alltronics Holdings Limited (stock code: 833.HK) between March 2017 and December 2018, an independent non- executive director of Winto Group (Holdings) Limited (stock code: 8238.HK) between April 2019 and November 2019 and Tenwow International Holdings Limited (stock code: 1219.HK) between November 2018 and November 2020.
Dr. LIU Ta-pei, aged 70, is an independent non-executive Director of the Company. He is also a member of the audit committee, the remuneration committee and the nomination committee of the Company respectively. He graduated from National Chung-Hsing University in Taiwan. After graduation, he continued his studies in National Cheng-Chi University, Taiwan and the University of Southern California, U.S.A. and obtained Master of Science and MBA degrees respectively. He was then conferred his Doctoral degree in public administration from the University of La Verne, U.S.A, and the Doctoral degree in Finance from Shanghai University of Finance and Economics. Apart from his strong educational background, Dr. LIU has been active in the financial field for more than 24 years. Dr. LIU was previously the executive director of Huisheng International Holdings Limited, which is listed on the Main Board of the Stock Exchange (Stock code: 1340.HK) from June 2016 to February 2020. He was previously the director of Mega Financial Holdings Company Limited (“Mega Financial Holdings”), which is listed on the Taiwan Stock Exchange Corporation (Stock code: 2886.TW) and also served as the chairman of Mega Securities Co., Ltd, a subsidiary of Mega Financial Holdings. He had also been the director of Global Securities Finance Corporation, Chung Hsing Bills Finance Corporation, and Central Investment Holding Company, and the chairman of Jen Hwa Investment Holding Company. Dr. LIU had served China Development Industrial Bank, one of the top management of Taiwan’s largest Investment Banks. He had also been the chief executive officer and an executive director of the Core Pacific-Yamaichi Group in Hong Kong. Dr. LIU was ranked as one of the ‘Top Ten Intelligent Financial Personnel in Greater China’ and he was conferred the ‘Best Integrity Award’ in 2008. He was also granted the honour of “Golden Peak Award of Outstanding Corporation Leaders in Taiwan” in 1998. Dr. LIU is currently a member of the Hong Kong-Taiwan Business Co-operation Committee. He joined the Group in February 2017.
Mr. CHAU Wai Wah Fred, aged 59, is an independent non-executive director and a member of the audit committee, remuneration committee and nomination committee of the Company. He was formerly the Head of the Office of Dutiable Commodities Administration of Hong Kong Customs and Excise Department (C&ED) and retired with rank of Senior Superintendent. He has served the C&ED for 34 years with wide range of exposure including intellectual property rights (IPR) protection, anti-smuggling, anti-narcotics, intelligence and liaisons and dutiable commodities administration. Mr. Chau has served as the Divisional Commander and Group Head of the Intellectual Property Investigation Bureau to combat on organized transnational crimes, in particular in IPR infringement cases with the Mainland and overseas counterparts. Mr. Chau was awarded the honours of Customs and Excise Medal for Meritorious Service (C.M.S.M.) by the Chief Executive in the 2017 honours presentation ceremony.